Literature DB >> 15085186

West Nile virus: a growing concern?

L Hannah Gould1, Erol Fikrig.   

Abstract

West Nile virus was first detected in North America in 1999 and has subsequently spread throughout the United States and Canada and into Mexico and the Caribbean. This review describes the epidemiology and ecology of West Nile virus in North America and the prospects for effective treatments and vaccines.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15085186      PMCID： PMC385414          DOI： 10.1172/JCI21623

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  79 in total

1.  Experimental infection of horses with West Nile virus and their potential to infect mosquitoes and serve as amplifying hosts.

Authors:  M L Bunning; R A Bowen; B Cropp; K Sullivan; B Davis; N Komar; M Godsey; D Baker; D Hettler; D Holmes; C J Mitchell
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

2.  Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States.

Authors:  David W C Beasley; C Todd Davis; Hilda Guzman; Dana L Vanlandingham; Amelia P A Travassos da Rosa; Ray E Parsons; Stephen Higgs; Robert B Tesh; Alan D T Barrett
Journal:  Virology       Date:  2003-05-10       Impact factor: 3.616

3.  Potential North American vectors of West Nile virus.

Authors:  M J Turell; M R Sardelis; D J Dohm; M L O'Guinn
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

Review 4.  West Nile virus: a primer for the clinician.

Authors:  Lyle R Petersen; Anthony A Marfin
Journal:  Ann Intern Med       Date:  2002-08-06       Impact factor: 25.391

5.  Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis.

Authors:  Robert B Tesh; Amelia P A Travassos da Rosa; Hilda Guzman; Tais P Araujo; Shu-Yuan Xiao
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

6.  Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines.

Authors:  N Kanesa-Thasan; J R Putnak; J A Mangiafico; J E Saluzzo; G V Ludwig
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

7.  Transmission of West Nile virus from an organ donor to four transplant recipients.

Authors:  Martha Iwamoto; Daniel B Jernigan; Antonio Guasch; Mary Jo Trepka; Carina G Blackmore; Walter C Hellinger; Si M Pham; Sherif Zaki; Robert S Lanciotti; Susan E Lance-Parker; Carlos A DiazGranados; Andrea G Winquist; Carl A Perlino; Steven Wiersma; Krista L Hillyer; Jesse L Goodman; Anthony A Marfin; Mary E Chamberland; Lyle R Petersen
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

8.  West Nile Virus activity--United States, 2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-06-14       Impact factor: 17.586

9.  Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases.

Authors:  John T Roehrig; Denis Nash; Beth Maldin; Anne Labowitz; Denise A Martin; Robert S Lanciotti; Grant L Campbell
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

10.  Experimental infection of North American birds with the New York 1999 strain of West Nile virus.

Authors:  Nicholas Komar; Stanley Langevin; Steven Hinten; Nicole Nemeth; Eric Edwards; Danielle Hettler; Brent Davis; Richard Bowen; Michel Bunning
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883
View more
  34 in total

1.  Emerging infectious diseases.

Authors:  Vincent R Racaniello
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

2.  Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.

Authors:  Claire Y-H Huang; Shawn J Silengo; Melissa C Whiteman; Richard M Kinney
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody.

Authors:  Bärbel Kaufmann; Grant E Nybakken; Paul R Chipman; Wei Zhang; Michael S Diamond; Daved H Fremont; Richard J Kuhn; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

4.  Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection.

Authors:  Chyan-Jang Lee; Ching-Len Liao; Yi-Ling Lin
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.

Authors:  L Hannah Gould; Jianhua Sui; Harald Foellmer; Theodore Oliphant; Tian Wang; Michel Ledizet; Akikazu Murakami; Kristin Noonan; Cassandra Lambeth; Kalipada Kar; John F Anderson; Aravinda M de Silva; Michael S Diamond; Raymond A Koski; Wayne A Marasco; Erol Fikrig
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 6.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Authors:  Nathalie Bonafé; Joseph A Rininger; Richard G Chubet; Harald G Foellmer; Stacey Fader; John F Anderson; Sandra L Bushmich; Karen Anthony; Michel Ledizet; Erol Fikrig; Raymond A Koski; Paul Kaplan
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

Review 8.  CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?

Authors:  Kavon Rezai-Zadeh; David Gate; Terrence Town
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-11       Impact factor: 4.147

9.  Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody.

Authors:  Hameeda Sultana; Harald G Foellmer; Girish Neelakanta; Theodore Oliphant; Michael Engle; Michel Ledizet; Manoj N Krishnan; Nathalie Bonafé; Karen G Anthony; Wayne A Marasco; Paul Kaplan; Ruth R Montgomery; Michael S Diamond; Raymond A Koski; Erol Fikrig
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

10.  IL-10 signaling blockade controls murine West Nile virus infection.

Authors:  Fengwei Bai; Terrence Town; Feng Qian; Penghua Wang; Masahito Kamanaka; Tarah M Connolly; David Gate; Ruth R Montgomery; Richard A Flavell; Erol Fikrig
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.